海外の治験の状況「前立腺癌」での検索結果
241件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- A phase I/II trial of Cabazitaxel +/- Rhenium-188 HEDP in patients with metastatic castration resistant prostate cancer who progressed on or after a docetaxel containing treatment. The ReCab trial
- Metastatic prostate cancer/bone metastases;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]
- Netherlands
- 2012-08-01
Authorised
- The study compares the therapy of abiraterone acetate plus LHRH-therapy with the therapy of abiraterone acetate allone in patients with recurrent prostate cancer in spite of chemotherapy and castration, the therapy for every single patient gets select by chance
- Medically castrated male patients with chemotherapy-naïve, castration-resistant, metastatic CRPC who have shown tumor progression and are non- or mildly-symptomatic MedDRA version: 16.1 Level: LLT Classification code 10066489 Term: Progression of prostate cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Germany
- 2013-12-23
Authorised
- Randomized, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix or Leuprolide
- Advanced Prostate Cancer br>MedDRA version: 20.0 Level: PT Classification code 10071119 Term: Hormone-dependent prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Canada, Czech Republic, France, Germany, Hungary, Slovakia, United States
- 2018-02-13
Authorised
- An open label, multiple dose Phase III clinical study in patients with prostate cancer to investigate the clinical efficacy and safety of a new GnRH implant (ACINO Goserelin 10.8 mg Implant) applied every 84 days for 168 days - C_30060_P3_03
- prostate cancer br>MedDRA version: 12.0 Level: LLT Classification code 10060862 Term: Prostate cancer
- Germany
- 2009-10-13
Authorised
- Ensayo clínico abierto, aleatorizado, de grupos paralelos que compara degarelix frente a bloqueo androgénico combinado (goserelina + bicalutamida) en términos de reducción de la puntuación en la escala internacional de síntomas prostáticos (IPSS) en pacientes con síntomas del tracto urinario inferior (LUTS) asociados a cáncer de próstata localmente avanzado A randomised, parallel-arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of reduction in International Prostate Symptom Score (IPSS), in patients with lower urinary tract symptoms (LUTS) secondary to locally advanced prostate cancer - FE200486 CS28
- Cáncer de próstata MedDRA version: 9.1 Level: PT Classification code 10060862 Term: Prostate cancer
- Germany, Spain, United Kingdom
- 2008-09-18
Authorised
- A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastatic Androgen-Independent Prostate Cancer - VENICE
- Patients with metastatic androgen-independent prostate cancer
- Czech Republic, Denmark, Estonia, France, Germany, Hungary, Italy, Netherlands, Portugal, Spain, Sweden, United Kingdom
- 2007-06-22
Authorised
- The effects of pretreatment with androgen blocking hormones before brachytherapy for prostate cancer on the course of PSA and testosterone after treatment
- Localized prostate cancer br>MedDRA version: 14.0 Level: LLT Classification code 10007050 Term: Cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Netherlands
- 2011-11-17
Authorised
- Randomized, open-label, parallel-group, multi-centre phase II clinical trial with active cellular immunotherapy DCVAC/PCa in patients with localized high-risk prostate cancer after primary radiotherapy
- localized high-risk prostate cancer br>MedDRA version: 20.0 Level: PT Classification code 10071119 Term: Hormone-dependent prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Czech Republic
- 2011-11-02
Authorised
- Investigation of the effect of Zoledronic acid on circulating tumor cells in the blood in men with hormone refractory metastatic prostate cancer.
- hormone refractory metastatic prostate cancer ;Therapeutic area: Diseases [C] - Cancer [C04]
- Germany
- 2011-08-12
Authorised
- KEES- A single arm phase II trial of the peroral regimen KEES (Ketokonazole, Etoposide, Estramustine, Sendoxan) in patients with Castration Resistant Prostate Cancer (CRPC) - KEES- a phase II study in patients with CRPC
- Men with castration resistant prostate cancer br>MedDRA version: 14.0 Level: LLT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- Sweden
- 2011-06-30